SAT-443 Osilodrostat Has No Clinically Relevant Effect on the Pharmacokinetic (PK) Profile of a Monophasic Oral Contraceptive in Healthy Females Receiving Cortisol Replacement Therapy

Background: Osilodrostat, a potent oral 11β-hydroxylase inhibitor, is in Phase 3 development for endogenous Cushing’s syndrome (CS). As CS occurs mostly in females of childbearing age, it is important to determine the effect of osilodrostat on oral contraceptives (OCs). We report the effect of multi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Breitschaft, Astrid, Tauchmanova, Libuse, Han, Kevin, Atkinson, Susan, Nauwelaerts, Heidi, Sengupta, Tirtha, Zic, Ivanka, Burgmeyer, Lisa, Pedroncelli, Alberto
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2019
Assuntos:
Neuroendocrinology and Pituitary
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552051/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-443
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados